{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:42:15Z","timestamp":1761129735753,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006022","name":"Minist\u00e8re des Affaires Sociales, de la Sant\u00e9 et des Droits des Femmes","doi-asserted-by":"publisher","award":["P090105"],"award-info":[{"award-number":["P090105"]}],"id":[{"id":"10.13039\/501100006022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The diagnostic performance of <jats:sup>18<\/jats:sup>F-sodium fluoride positron emission tomography\/computed tomography (PET\/CT) (NaF), <jats:sup>18<\/jats:sup>F-fluorocholine PET\/CT (FCH) and diffusion-weighted whole-body magnetic resonance imaging (DW-MRI) in detecting bone metastases in prostate cancer (PCa) patients with first biochemical recurrence (BCR) has already been published, but their cost-effectiveness in this indication have never been compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed trial-based and model-based economic evaluations. In the trial, PCa patients with first BCR after previous definitive treatment were prospectively included. Imaging readings were performed both on-site by local specialists and centrally by experts. The economic evaluation extrapolated the diagnostic performances of the imaging techniques using a combination of a decision tree and Markov model based on the natural history of PCa. The health states were non-metastatic and metastatic BCR, non-metastatic and metastatic castration-resistant prostate cancer and death. The state-transition probabilities and utilities associated with each health state were derived from the literature. Real costs were extracted from the National Cost Study of hospital costs and the social health insurance cost schedule.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was no significant difference in diagnostic performance among the 3 imaging modalities in detecting bone metastases. FCH was the most cost-effective imaging modality above a threshold incremental cost-effectiveness ratio of 3000\u20ac\/QALY when imaging was interpreted by local specialists and 9000\u20ac\/QALY when imaging was interpreted by experts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>FCH had a better incremental effect on QALY, independent of imaging reading and should be preferred for detecting bone metastases in patients with biochemical recurrence of prostate cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01501630\">NCT01501630<\/jats:ext-link>. Registered 29 December 2011.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12880-020-00425-y","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T19:02:51Z","timestamp":1583175771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of 18F-sodium fluoride PET\/CT, 18F-fluorocholine PET\/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4882-9366","authenticated-orcid":false,"given":"Mathieu","family":"Gauth\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Zarca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrielle","family":"Aveline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Lecouvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sona","family":"Balogova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Cussenot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-No\u00ebl","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Durand-Zaleski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"425_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359\u201386.","journal-title":"Int J Cancer"},{"key":"425_CR2","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","volume":"67","author":"ND James","year":"2015","unstructured":"James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with newly diagnosed metastatic prostate cancer in the \u201cdocetaxel era\u201d: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019). Eur Urol. 2015;67:1028\u201338.","journal-title":"Eur Urol"},{"key":"425_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","volume":"184","author":"M N\u00f8rgaard","year":"2010","unstructured":"N\u00f8rgaard M, Jensen A\u00d8, Jacobsen JB, Cetin K, Fryzek JP, S\u00f8rensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184:162\u20137.","journal-title":"J Urol"},{"key":"425_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0360-3016(03)01442-1","volume":"58","author":"D Singh","year":"2004","unstructured":"Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol. 2004;58:3\u201310.","journal-title":"Int J Radiat Oncol"},{"key":"425_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"425_CR6","doi-asserted-by":"publisher","unstructured":"Gauth\u00e9 M, Aveline C, Lecouvet F, Michaud L, Rousseau C, Tassart M, et al. Impact of sodium 18F-fluoride PET\/CT, 18F-fluorocholine PET\/CT and whole-body diffusion-weighted MRI on the management of patients with prostate cancer suspicious for metastasis: a prospective multicentre study. World J Urol. 2018. https:\/\/doi.org\/10.1007\/s00345-018-2547-5.","DOI":"10.1007\/s00345-018-2547-5"},{"key":"425_CR7","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1007\/s00259-018-4058-4","volume":"45","author":"HD Zacho","year":"2018","unstructured":"Zacho HD, Nielsen JB, Afshar-Oromieh A, Haberkorn U, de Souza N, De Paepe K, et al. Prospective comparison of 68Ga-PSMA PET\/CT, 18F-sodium fluoride PET\/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:1884\u201397.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"425_CR8","doi-asserted-by":"publisher","first-page":"e0191487","DOI":"10.1371\/journal.pone.0191487","volume":"13","author":"Q Gillebert","year":"2018","unstructured":"Gillebert Q, Huchet V, Rousseau C, Cochet A, Olivier P, Courbon F, et al. 18F-fluorocholine PET\/CT in patients with occult biochemical recurrence of prostate cancer: detection rate, impact on management and adequacy of impact. A prospective multicentre study. PLOS ONE. 2018;13:e0191487.","journal-title":"PLOS ONE"},{"key":"425_CR9","first-page":"448","volume":"55","author":"W Langsteger","year":"2011","unstructured":"Langsteger W, Balogova S, Huchet V, Beheshti M, Paycha F, Egrot C, et al. Fluorocholine (18F) and sodium fluoride (18F) PET\/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging. 2011;55:448\u201357.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"425_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, Santis MD, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630\u201342.","journal-title":"Eur Urol"},{"key":"425_CR11","unstructured":"Professionals S-O. EAU Guidelines: Oncology Guidelines. Uroweb https:\/\/uroweb.org\/individual-guidelines\/oncology-guidelines\/. Accessed 11 Dec 2019."},{"key":"425_CR12","unstructured":"Recommandations de l\u2019A.F.U. class\u00e9es par ann\u00e9e | Urofrance. https:\/\/www.urofrance.org\/outils-et-recommandations\/recommandations\/recommandations-afu\/classees-par-annee.html. Accessed 11 Dec 2019."},{"key":"425_CR13","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1007\/s00259-008-0788-z","volume":"35","author":"M Beheshti","year":"2008","unstructured":"Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET\u2013CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766\u201374.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"425_CR14","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s002560050434","volume":"27","author":"BC Vande Berg","year":"1998","unstructured":"Vande Berg BC, Malghem J, Lecouvet FE, Maldague B. Classification and detection of bone marrow lesions with magnetic resonance imaging. Skelet Radiol. 1998;27:529\u201345.","journal-title":"Skelet Radiol"},{"key":"425_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s003300050038","volume":"10","author":"D Vanel","year":"2000","unstructured":"Vanel D, Dromain C, Tardivon A. MRI of bone marrow disorders. Eur Radiol. 2000;10:224\u20139.","journal-title":"Eur Radiol"},{"key":"425_CR16","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/0272989X9301300409","volume":"13","author":"FA Sonnenberg","year":"1993","unstructured":"Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Mak. 1993;13:322\u201338.","journal-title":"Med Decis Mak"},{"key":"425_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12885-017-3922-0","volume":"18","author":"RK Hernandez","year":"2018","unstructured":"Hernandez RK, Wade SW, Reich A, Pirolli M, Liede A, Lyman GH. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer. 2018;18:44.","journal-title":"BMC Cancer"},{"key":"425_CR18","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/j.canep.2012.07.012","volume":"36","author":"CJ Hirst","year":"2012","unstructured":"Hirst CJ, Cabrera C, Kirby M. Epidemiology of castration resistant prostate cancer: a longitudinal analysis using a UK primary care database. Cancer Epidemiol. 2012;36:e349\u201353.","journal-title":"Cancer Epidemiol"},{"key":"425_CR19","unstructured":"Institut national de la statistique et des \u00e9tudes \u00e9conomiques. Esp\u00e9rance de vie - Mortalit\u00e9 \u2212 Tableaux de l\u2019\u00e9conomie fran\u00e7aise. https:\/\/www.insee.fr\/fr\/statistiques\/3676610?sommaire=3696937. Accessed 14 May 2019."},{"key":"425_CR20","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate Cancer. J Clin Oncol. 2005;23:2918\u201325.","journal-title":"J Clin Oncol"},{"key":"425_CR21","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813\u201322.","journal-title":"Lancet"},{"key":"425_CR22","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3109\/0284186X.2012.760848","volume":"52","author":"S Torvinen","year":"2013","unstructured":"Torvinen S, F\u00e4rkkil\u00e4 N, Sintonen H, Saarto T, Roine RP, Taari K. Health-related quality of life in prostate cancer. Acta Oncol. 2013;52:1094\u2013101.","journal-title":"Acta Oncol"},{"key":"425_CR23","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/S1470-2045(18)30456-X","volume":"19","author":"F Saad","year":"2018","unstructured":"Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:1404\u201316.","journal-title":"Lancet Oncol"},{"key":"425_CR24","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jval.2015.08.012","volume":"18","author":"AJ Lloyd","year":"2015","unstructured":"Lloyd AJ, Kerr C, Penton J, Knerer G. Health-related quality of life and health Utilities in Metastatic Castrate-Resistant Prostate Cancer: a survey capturing experiences from a diverse sample of UK patients. Value Health. 2015;18:1152\u20137.","journal-title":"Value Health"},{"key":"425_CR25","unstructured":"Agence technique de l\u2019information sur l\u2019hospitalisation. R\u00e9f\u00e9rentiel national de co\u00fbts des prises en charge (ENC). https:\/\/www.scansante.fr\/applications\/donnees-de-couts. Accessed 13 Feb 2019."},{"key":"425_CR26","unstructured":"L\u2019Assurance Maladie. Base des M\u00e9dicaments et Informations Tarifaires. http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/index_presentation.php?p_site=AMELI. Accessed 13 Feb 2019."},{"key":"425_CR27","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Choix m\u00e9thodologiques pour l\u2019\u00e9valuation \u00e9conomique \u00e0 la HAS. https:\/\/www.has-sante.fr\/portail\/jcms\/r_1499251\/fr\/choix-methodologiques-pour-l-evaluation-economique-a-la-has. Accessed 21 Feb 2019."},{"key":"425_CR28","unstructured":"Filipovi\u0107-Pierucci A, Zarca K, Durand-Zaleski I. Markov Models for Health Economic Evaluations: The R Package heemod. ArXiv170203252 Stat. 2017. http:\/\/arxiv.org\/abs\/1702.03252. Accessed 26 Mar 2019."},{"key":"425_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS)\u2014explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16:231\u201350.","journal-title":"Value Health"},{"key":"425_CR30","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00256-014-1903-9","volume":"43","author":"G Shen","year":"2014","unstructured":"Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET\/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skelet Radiol. 2014;43:1503\u201313.","journal-title":"Skelet Radiol"},{"key":"425_CR31","first-page":"3770","volume":"20","author":"F Barchetti","year":"2016","unstructured":"Barchetti F, Stagnitti A, Megna V, Al Ansari N, Marini A, Musio D, et al. Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment. Eur Rev Med Pharmacol Sci. 2016;20:3770\u20136.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"425_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","volume":"71","author":"AR Padhani","year":"2017","unstructured":"Padhani AR, Lecouvet FE, Tunariu N, Koh D-M, De Keyzer F, Collins DJ, et al. METastasis reporting and data system for prostate Cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate Cancer. Eur Urol. 2017;71:81\u201392.","journal-title":"Eur Urol"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-020-00425-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12880-020-00425-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-020-00425-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:21:30Z","timestamp":1614644490000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-020-00425-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["425"],"URL":"https:\/\/doi.org\/10.1186\/s12880-020-00425-y","relation":{},"ISSN":["1471-2342"],"issn-type":[{"type":"electronic","value":"1471-2342"}],"subject":[],"published":{"date-parts":[[2020,3,2]]},"assertion":[{"value":"8 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The French multicentre study \u201cFLUPROSTIC\u201d (NCT01501630) was conducted in accordance with the Declaration of Helsinki. It was approved by the \u201cComit\u00e9 de protection des personnes Ile-de-France X\u201d (IDRCB 2011-A0101\u201340), which is an official independent national ethical research committee certified by the French Ministry of Health.All patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}